Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - Immunome, Inc. reported a quarterly loss of $0.84 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.68, and compared to a loss of $0.54 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $2.74 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 10.81%, and down from $3.83 million in the same quarter last year [2] - Over the last four quarters, Immunome has only surpassed consensus EPS estimates once and has consistently missed revenue estimates [2] Stock Performance - Immunome shares have declined approximately 21.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.75 on revenues of $2.33 million, and for the current fiscal year, it is -$3.13 on revenues of $9.33 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Immunome's stock performance [5]